Introduction
In somatic cells, Pol b is assumed to be strictly involved in the DNA synthesis step of the single-nucleotide base excision repair (BER) pathway (Sobol et al., 1996) , which processes small DNA lesions such as oxidized or alkylated bases. Pol b can be distinguished from the polymerases involved in the genome replication by its high in®delity in replicating DNA, due to the lack of associated proofreading activity (Kornberg and Baker, 1992) , a poor ability to discriminate oxidized nucleotides (Kamath-Loeb et al., 1997) , and an ability to eciently incorporate into DNA nucleotide analogs such as ddCTP (Copeland et al., 1992) , AZT-TP (Parker et al., 1991) , as well as ara-CTP (Ohno et al., 1988) . Even during the single nucleotide gap ®lling step of the BER pathway, Pol b has been shown to be errorprone (Oshero et al., 1999) . Probably because of these error-prone features, its expression, constant and low throughout the cell cycle (Zmudzka et al., 1988) , is tightly regulated. At both RNA and protein levels, Pol b has been shown to be overexpressed in a substantial number of cancer cells (Canitrot et al., 2000; Gomi et al., 1996; Scanlon et al., 1989; Srivastava et al., 1999) . It was found more than 10-fold overrepresented in prostate, breast or colon cancer tissues, compared to adjacent normal tissues (Srivastava et al., 1999) . In addition we showed that intracellular pool of Pol b is increased in human ovarian cancer cells (Canitrot et al., 2000) and chronic myeloid leukemia cells from patients (unpublished results) .
Pol b has been demonstrated to replicate in vitro past DNA lesions formed by the antitumor agent cisplatin, which is widely used in the treatment of ovarian, testicular, head and neck carcinomas, and whose therapeutic eects result from covalent binding to DNA, inhibiting replication and/or transcription (Pil and Lippard, 1997) . In addition to being genotoxic, the cisplatin lesions are also mutagenic and this mutagenicity could thus play a role in the generation of second tumors in cancer patients. Another major obstacle for the successful treatment of cancer by cisplatin is drug resistance. Most of the studies on platinum resistance have focused on decreased drug uptake, enhanced nucleotide excision repair, or loss of DNA mismatch repair (Andrews and Howell, 1990 ). An additional mechanism of resistance may be the consequence of an increased capacity of the cell to tolerate platinum-DNA lesions. We (Canitrot et al., 1998; Homann et al., 1995) and others (Vaisman and Chaney, 2000; Vaisman et al., 1999) have shown that puri®ed Pol b has the potential to eciently catalyze error-prone translesion synthesis in vitro across the major intra-strand crosslinks at the N-7 positions of adjacent guanine bases. This mechanism has been proposed to be the primary mechanism that caused decreased cisplatin sensitivity in a series of cell lines, especially in the human ovarian carcinoma 2008/C13*5.25 cells where enhanced translesion synthesis of platinum lesions, ranging from 2 ± 5-fold compared to sensitive cell lines, has been observed (Johnson et al., 1997) . However, the molecular determinants of the mechanisms responsible for such a tolerance are largely unknown. The data presented here suggest a key involvement of up-regulated Pol b in the bypass replication process in the 2008/C13*5.25 cells.
It has been reported that the 2008/C13*5.25 cells were also sensitive to the cytotoxic action of 6-thioguanine, a nucleotide analog used in anticancer treatments, as compared to the parental 2008 cells (Aebi et al., 1996) . The poor ability of Pol b to discriminate nucleotides pushed us to test the possi-bility that the 2008/C13*5.25 cells would possess the ability to increase 6-TG incorporation into DNA during DNA synthesis through the action of excess Pol b. Our observations presented in this study support this hypothesis.
Taken together, these data indicate that DNA pol b could be an important determinant of the drug sensitivity towards anticancer drugs. The relationship between the genetic signature of freshly diagnosticated tumors and the choice of the following therapeutic strategy is discussed.
Results
Nucleotide excision repair of cisplatin adducts is not increased in 2008/C13*5.25 cells Drug resistance is a major obstacle for the successful treatment of cancer with cisplatin. Cell lines exhibit dierent mechanisms that account for their acquired cisplatin resistance. Among these mechanisms, it has been described (Andrews and Howell, 1990) (1) elevated levels of proteins such as glutathione which can sequester the drug before it reaches its pharmacological targets; (2) alteration in mismatch repair; (3) enhanced Nucleotide Excision Repair (NER) capacity; and (4) increased capacity of the cells to tolerate the lesions. The cisplatin-resistant phenotype of the 2008/ C13*5.25 cells, which have been selected in vitro after repeated exposure to the drug (Aebi et al., 1996) , resulted neither from elevated glutathione level (Andrews et al., 1985) , nor alteration in DNA mismatch repair proteins (Aebi et al., 1996) . We tested the possibility that NER activity could be enhanced in these cells by using a standard in vitro repair synthesis assay (Wood et al., 1988) which reconstitutes all the steps of the pathway, recognition of lesion, incision of the damaged strand on either side of the targeted lesion, excision of the fragment carrying the lesion, and ®lling of the resulting gap followed by ligation. Cell extracts from 2008 and 2008/C13*5.25 cells were incubated with cisplatindamaged (pBS CDDP) and undamaged (pHM) plasmids in a repair synthesis reaction as indicated in Materials and methods. Figure 1 shows the photograph of ethidium bromide stained gel (upper part) and autoradiogram of the dried gel (lower part). We quanti®ed for both cell lines the same radiolabel incorporation in the damaged versus undamaged plasmid, demonstrating that the 2008/C13*5.25 cells did not exhibit a higher repair synthesis activity on cisplatin-DNA lesions, and suggesting that the resistance phenotype cannot be attributed to enhanced NER activity in these cells.
Replicative extracts from 2008/C13*5.25 cells are able to perform translesion synthesis of the bifunctional Pt-d(GpG) adduct By using an in vivo steady-state replication assay which measures the incorporation of [ 3 H]thymidine into nascent DNA strands, as a function of the number of platinum-DNA adducts present on the DNA following cisplatin treatment, it has been proposed that the cisplatin-resistant phenotype of the 2008/C13*5.25 cells could be due to their enhanced capability to tolerate cisplatin-DNA damages (Mamenta et al., 1994) . To investigate the bypass replication ability of these cells, we analysed the extension of a 5'-phosphorylated 17-mer oligonucleotide primer on untreated and cisplatindamaged 60-mer templates (Canitrot et al., 1998) bearing a single bifunctional Pt-d(GpG), the major platinum-DNA lesion. After these substrates were replicated, the products were resolved by polyacrylamide gel electrophoresis and visualized by autoradiography ( Figure 2 ). When untreated substrate was used, ecient primer extension reactions were detected for both cell extracts ( Figure 2 , left part). In the case of the cisplatin-modi®ed 60-mer substrate, the reaction products generated by the 2008 cell extracts migrated as a 39-mer DNA, indicating complete arrest of replication opposite the dT base preceding the unique Pt-d(GpG) adduct. In contrast, DNA synthesis mediated by 2008/ C13*5.25 cell extracts proceeded past the site of platinum damage. In most replicative attempts, the cell extracts were able to add one addition nucleotide opposite the ®rst platinated guanine. In a minority of replicative attempts, they were able to bypass the adduct altogether generating longer and even full length 60-mer product. These data were reproduced in four independent experiments and we systematically observed greater level of labeled DNA synthesis products on the adducted template for the 2008/ C13*5.25 extracts as compared to the 2008 extract ( Figure 2 , right part). We already reported this observation (enhanced radioactivity level in reactions where bypass synthesis occurs) in previous studies with puri®ed Pol b (Homann et al., 1995) or with cell extracts from other sources (Canitrot et al., 1998) , the reasons for this observation being still unclear. Taken together, these data indicated that 2008/C13*5.25 extracts were able to catalyze translesion replication, while the control cell extracts were not.
The 2008/C13*5.25 cell line shows enhanced expression and activity of Pol b
Our laboratory (Canitrot et al., 1998; Homann et al., 1995) and other groups (Vaisman and Chaney, 2000; Vaisman et al., 1999) (Figure 3a ). An enhanced expression of Pol b in the cisplatin-resistant cell line was observed in comparison with the parental cell line. Quantitative analysis by phosphoImager scanning showed an eightfold increase in the expression. To test whether the increased expression of Pol b was correlated with elevated Pol b activity, replicative cell extracts were prepared and tested for their sensitivity to the nucleotide analog ddCTP, known to strongly inhibit in vitro and in vivo the DNA synthesis (Canitrot et al., 1999b) . Replication of a 5'-32 P-labeled primed 60-mer DNA template was replicated at 378C for 1 h by 3 mg of cell extract in the absence or presence of ddCTP at a ratio ddCTP/dCTP equal to 1. Arrows indicate the position of the primer (17) and the fully replicated product (60). Quanti®cation is the result of three separate experiments done with two independent preparations of cell extracts Oncogene DNA polymerase b b and drug sensitivity V Bergoglio et al catalyzed by Pol b compared to the replicative enzymes (Bouayadi et al., 1997; Copeland et al., 1992) . In vitro, it has been demonstrated that Pol b incorporated the ddCMP chain terminator with an eciency comparable to that of dCMP when an oligonucleotide template was used, while it is a poor substrate of the replicative DNA polymerases d and e (Copeland et al., 1992) . A G-rich 60-mer oligonucleotide DNA template was annealed to a 5'-phosphorylated 17-mer oligonucleotide (Canitrot et al., 1999b) and primer extension reactions were conducted in vitro using cell extracts. The newly synthesized DNA products were resolved by polyacrylamide gel electrophoresis and visualized by autoradiography. Figure 3b shows the replication of the DNA template in absence or in presence of ddCTP at a dCTP/ddCTP ratio of 1. In absence of ddCTP, primer extension products (18-to 60-mer products) were observed for both extracts after 1 h incubation at 378C (Figure 3b , left part). Pol b activity was determined by monitoring the ability of the extracts to incorporate the chain terminator ddCTP, which inhibits the Pol b-mediated chain elongation and therefore results in the strong disappearance of the primer extension products. As it can be observed in Figure 3b The strong potential displayed by Pol b to incorporate nucleotide analogs into DNA (Copeland et al., 1992; Ohno et al., 1988; Parker et al., 1991) pushed us to examine whether base analogs used in chemotherapy such as 6-thioguanine may promote greater genotoxic eects on cells overexpressing the polymerase. We conducted clonogenic experiments and demonstrated that the 2008/C13*5.25 cells are dramatically more sensitive to the antimetabolite analog (Figure 4a ). To investigate the speci®c role of Pol b in this mechanism, we used isogenic CHO cell lines which, in contrast to the couple of the human ovarian tumor cells, only dier by the amount of expressed Pol b. One of these cell lines (CHO Pol b ::Sh), transfected with the Pol b cDNA, overexpresses the protein approximately sevenfold compared to the other one, the correspondent control (CHO Sh) (Canitrot et al., 1998) . We found that the CHO Pol b ::Sh cells were hypersensitive to 6-TG, demonstrating that excess Pol b could be directly responsible for a 6-TG sensitivity phenotype. These ®ndings suggest that the elevated amount of Pol b in the 2008/C13*5.25 cells could contribute to their hypersensitivity towards 6-TG. A major determinant of the cytotoxic action of this antimetabolite is based on its incorporation into DNA (Nelson et al., 1975) . In order to compare 6-TG incorporation in 2008/C13*5.25 and 2008 cells, we used a precolumn derivatization HPLC technique, a method based on enzymatic degradation of DNA to 2'-deoxyribonucleosides and the derivatization of released 2'-deoxy-6-thioguanosine with a thiol-reactive reagent containing a 7-amino-4-methylcoumarin-3-acetic acid¯uorophore. The 2'-deoxy-6-thioguanosine-7-amino-4-methylcoumarin-3-acetic acid adduct is resolved by reverse-phase HPLC and quanti®ed uorometrically. As shown in Figure 5 , a signi®cantly higher amount of 6-TG than the corresponding parental cell lines was incorporated by the CHO-Pol b cells (1.4-fold) and the cisplatin-resistant 2008/C13 5*25 cells (twofold), supporting a direct contribution of Pol b to the hypersensitivity towards this antitumor drug. It has to be pointed out that, for a comparable amount of 6-TG incorporated into DNA, the degree of toxicity is dierent for the rodent cells and the human tumor cells. Other mechanisms, such as incorporation into RNA of 6-TG, inhibition of (Grindey, 1979) could also aect cell survival and their dierential eciencies may explain the dierences observed.
Discussion
Pol b is an error-prone enzyme poorly expressed, whose activity is delimited to the DNA repair pathway of base-excision repair (BER) in normal somatic cells (Sobol et al., 1996) . We have previously demonstrated that an excess of Pol b in cells resulted in an increased mutagenesis (Canitrot et al., 1998 (Canitrot et al., , 1999b , and proposed that the enzyme, in the context of its overexpression, may produce a mutator phenotype in some cancer cells that may contribute to tumor progression (Canitrot et al., 1999a) . High levels of Pol b have been detected in cell lines or tumor tissue from ovarian, gliomas, breast and colon adenocarcinomas (Canitrot et al., 2000; Gomi et al., 1996; Scanlon et al., 1989; Srivastava et al., 1999) . In the current study we found that the 2008/C13*5.25 human ovarian tumor cells exhibited a high expression and activity of Pol b, which consequently mediate bypass replication across a p(GpG) intrastrand cisplatin adduct. The ability of these cells to tolerate platinated damages had been previously demonstrated but the molecular basis of such phenomenon was not understood (Mamenta et al., 1994) . The data described here open the possibility that excess Pol b could participate to the translesional replication process and subsequently to the resistance phenotype. Neither increased in nucleotide excision repair (Figure 1 of this study), nor elevated glutathione level (Andrews et al., 1985) , nor alteration in DNA mismatch repair protein (Aebi et al., 1996) were observed in 2008/C13*5.25 compared to 2008 cells, suggesting that bypass replication may be predominant to explain cisplatin resistance. In cases where the coding properties of a damaged base are altered, such translesion synthesis can be mutagenic (Homann et al., 1996a) and could therefore generate cells with stronger mutator phenotypes during the course of the treatment. The observation that cisplatin is mutagenic in mammalian cells has raised concerns about its potential as a human carcinogen. Studies of tumorigenicity of cisplatin in rodents have demonstrated that this drug can produce preneoplasic and neoplasic lesions in multiple tissues (Diwan et al., 1995) . Translesion synthesis across cisplatin DNA adducts by excess Pol b could thus be a key determinant in the activation of transforming genes, and could therefore be part of the process of tumorigenicity induced by this drug. The identi®ca-tion of the mechanisms of cisplatin bypass replication should allow re®nement of strategies aimed at minimizing this adverse eect. It has to be pointed out that other DNA polymerases might be involved in such bypass replication mechanism. New cellular error-prone DNA polymerases have been recently described (Matsuda et al., 2000; Washington et al., 1999) which belong to the superfamily of DNA polymerases that are able to bypass lesions in DNA (Woodgate, 1999) . Among these enzymes that have been isolated in human cells, Pol z (Vaisman et al., 1999) and Pol Z (Vaisman et al., 2000) have been shown to catalyze bypass replication of platinum adducts in vitro, suggesting the possible involvement of deregulation of expression of such enzymes in the platinum resistance phenotype.
One of the main characteristics of Pol b is its low capacity to discriminate between nucleotide analogs (Bouayadi et al., 1997; Kamath-Loeb et al., 1997) . We hypothesized that cells up-regulating Pol b may display hypersensitivity to chemotherapeutic drugs which are nucleotides analogs such as 6-TG. This agent is metabolized into the cells to the deoxynucleo- tide form and incorporated into DNA. Once incorporated into DNA, it will impair the DNA function and kill the cells. Our results clearly show that the 2008/ C13*5.25 cell line exhibit a supersensitivity to 6-TG which is related to an increased incorporation of the triphosphorylated form into DNA. The ®ndings that increased level of Pol b in CHO cells produced hypersensitivity to 6-TG and increased incorporation of 6-TG into DNA as compared to its isogenic control cell line strongly suggest that the overproduced enzyme in the 2008/C13*5.25 cells may play a role in the hypersensitivity phenotype toward 6-TG. Extensive work have demonstrated the role of postreplicative mismatch repair in the toxicity of this agent (Swann et al., 1996) , but it is unlikely that this process explains the data observed here since the speci®c cell lines used in this study are not defective in mismatch repair.
The potential modulation of cisplatin resistance and hypersensitivity to 6-TG by a unique genetic event is of substantial clinical interest, since it may be possible to use such nucleotide analogs to eectively treat tumors up-regulating Pol b which are refractory to cisplatin. Our work underlines how elucidation of the modi®cations leading to drug resistance can help in designing therapeutic strategies that take advantage of the speci®c changes that cause the resistant phenotype.
Materials and methods

Cytotoxicity studies
Drugs were purchased from Sigma Co (Les Ulis, France). The human ovarian carcinoma cell line 2008 and its cisplatin-resistant derivative 2008/C13*5.25 were isolated and grown as described (Mamenta et al., 1994) . Establishment of CHO AA8 cells stably transfected with Pol b cDNA (Pol b::Sh) or the vector alone (Sh) as well as the growth conditions have been previously described (Bouayadi et al., 1997) . Cytotoxicity was determined by clonogenic assay. Cells (300/well) were plated in 6-well plates, allowed to attach overnight, and then treated with drugs diluted in complete medium at varying concentrations. Treatment was 1 h at 378C for cisplatin and continuous for 6-thioguanine. After 7 days, colonies were ®xed, stained with crystal violet, and colonies containing more than 50 cells were scored. Survival was expressed as the plating eciency of treated cells relative to the control. Results are the mean+s.d. of at least three separate experiments performed in duplicate.
Pol b Western blotting
Cell lysates (100 mg protein) were electrophoresed in a 12% SDS ± PAGE gel and transferred to a PVDF membrane. Blots were blocked in TBS-T (0.1% Tween) with 5% skim milk and incubated with Pol b polyclonal antibody (1/5000) (provided by Dr S Wilson, NIEHS, NC, USA) followed by incubation with horseradish peroxidase conjugated antirabbit IgG, and revealed using the ECL system (Amersham). Equal loading was determined using monoclonal antibody to actin (1/5000) (Chemicon, Euromedex, France).
Nucleotide excision repair activity assay
Cell extracts preparation was performed according to the previously described protocol (Homann et al., 1996b) . pBluescript KS+ plasmid was treated with cisplatin according to Hansson and Wood (1989) . The repair synthesis assay was performed as already described (Wood et al., 1988) . The reaction mixture (50 ml) contained 300 ng each of damaged pBluescript KS+ and untreated pHM14 closed circular plasmids, 2 mCi a [ 32 P]dCTP (800 Ci/mmol), 200 mg cell extract protein and 70 mM potassium glutamate in reaction buer containing 45 mM HEPES-KOH (pH 7.8), 7.4 mM MgCl 2 , 0.9 mM DTT, 0.4 mM EDTA, 2 mM ATP, 20 mM each dGTP, dATP and dTTP, 4 mM dCTP, 40 mM phosphocreatine, 2.5 mg phosphocreatine kinase, 3.4% glycerol and 18 mg bovine serum albumine as described.
DNA Pol b activity assay
Replicative cell extracts were prepared as previously described (Canitrot et al., 1998) . To study the Pol bdependent replication activity (Canitrot et al., 1999b) , a 60-mer oligonucleotide was hybridized to a 5'-32 P-labeled 17-mer synthetic primer to serve as a DNA template. This template (5 ng) was replicated in vitro by the cell extracts (5 mg protein) in reactions (15 ml) containing 45 mM HEPES-KOH (pH 7.8), 7 mM MgCl 2 , 1 mM DTT, 0.4 mM EDTA, 3.4% glycerol, 65 mM potassium glutamate, 18 mg of BSA, 200 mM each dATP, dGTP, and dTTP, and ddCTP in a ratio of ddCTP/dCTP equal at 1. At the end of the reaction, 5 ml of stopping buer (90% formamide/0.1% xylene cyanol/0.1% bromophenol blue/0.1 mM EDTA) were added. Samples were denatured for 10 min at 708C and loaded onto a 15% polyacrylamide/7 M urea/30% formamide gel. Gels were dried and processed on a PhosphoImager (Storm System, Molecular Dynamics TM) and the radioactivity quanti®ed (Image quant 1.1 software). Pol b activity was expressed as the percentage of inhibition by ddCTP of all products elongated from the primer.
Translesion replication assay
The cisplatin-modi®ed 60 mer was prepared as reported (Canitrot et al., 1998) and hybridized to a 5'-32 P-labeled 17 mer primer. Standard 15 ml reaction mixtures contained 5 ng of labeled intact or damaged substrate and 3 mg of cell extract protein in reaction buer containing 45 mM HEPES-KOH (pH 7.8), 7 mM MgCl 2 , 1 mM dithiothreitol, 0.4 mM EDTA, 300 mM each dATP, dCTP, dGTP, and dTTP, 3.4% glycerol, 65 mM mono-K glutamic acid, and 18 mg of bovine serum albumin. At the end of the reaction, samples were processed as mentioned above.
Measurement of 6-thioguanine incorporation into DNA
The protocol was based on the method previously described (Warren et al., 1995) .
DNA extraction and derivatization of thiopurine-containing DNA After exposure to 6TG for one doubling time, cells were harvested and washed. DNA was extracted from 4610 6 cells, treated with proteinase K for 10 min at 708C, and the mixture was puri®ed on a spin column by centrifugation. Prior to derivatization, DNA samples were denatured at 1008C for 5 min followed by rapid chilling on ice. To 100 ml of spin column euent, 10 ml of digestion buer (500 mM sodium acetate buer-10 mM MgCl 2 , pH 4.5) were added prior to the addition of 20 ml of 25 mg/ml P1 nuclease in 50 mM sodium acetate buer, 1 mM MgCl 2 , pH 4.5 and incubated at 428C for 1 h. One unit alkaline phosphatase was then added and the mixture incubated at 378C for 30 min followed by the addition of 10 ml of 400 mM formic acid and 60 ml methanol. Samples were derivatized overnight in the dark at room temperature following the addition of 5 ml of AMCA-HPDP.
Chromatography HPLC Separation Chromatography was performed on a Supelcosil LC-8 column maintained at 458C. Twenty-®ve ml of derivatized sample were injected and the mobile phase consisted of 0.2 M sodium formate buer (pH 4.0) : methanol and was delivered at a rate of 1 ml/min. Each run consisted of an isocratic phase for 10 min of 10% methanol, 95% 0.2 M formate buer (pH 4.0) followed by a linear gradient over 2 min to 40% methanol, 60% 0.2 M formate buer (pH 4.0) which was held isocratically for 25 min. The¯uorescence detector was operated at excitation and emission wavelengths of 345 and 450 nm, respectively, for the detection of derivatized thiodeoxyguanosine (S6dGuo-AMCA) and the absorbance detector at 461 nm for the detection of thymine. Compounds were identi®ed on the basis of retention time.
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